Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study

The utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of ca...

Full description

Bibliographic Details
Main Authors: Pei Yi Lee, Kellynn Qi Xuan Oen, Grace Rui Si Lim, Juanda Leo Hartono, Mark Muthiah, Daniel Q. Huang, Felicia Su Wei Teo, Andrew Yunkai Li, Anselm Mak, Nisha Suyien Chandran, Chris Lixian Tan, Peiling Yang, E Shyong Tai, Kay Wei Ping Ng, Joy Vijayan, Yee Cheun Chan, Li Ling Tan, Martin Beng-Huat Lee, Horng Ruey Chua, Wei Zhen Hong, Eng Soo Yap, Dawn K. Lim, Yew Sen Yuen, Yiong Huak Chan, Folefac Aminkeng, Alvin Seng Cheong Wong, Yiqing Huang, Sen Hee Tay
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/6/1308
id doaj-819b9f81de8649f18c8021bf0cf1e270
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Pei Yi Lee
Kellynn Qi Xuan Oen
Grace Rui Si Lim
Juanda Leo Hartono
Mark Muthiah
Daniel Q. Huang
Felicia Su Wei Teo
Andrew Yunkai Li
Anselm Mak
Nisha Suyien Chandran
Chris Lixian Tan
Peiling Yang
E Shyong Tai
Kay Wei Ping Ng
Joy Vijayan
Yee Cheun Chan
Li Ling Tan
Martin Beng-Huat Lee
Horng Ruey Chua
Wei Zhen Hong
Eng Soo Yap
Dawn K. Lim
Yew Sen Yuen
Yiong Huak Chan
Folefac Aminkeng
Alvin Seng Cheong Wong
Yiqing Huang
Sen Hee Tay
spellingShingle Pei Yi Lee
Kellynn Qi Xuan Oen
Grace Rui Si Lim
Juanda Leo Hartono
Mark Muthiah
Daniel Q. Huang
Felicia Su Wei Teo
Andrew Yunkai Li
Anselm Mak
Nisha Suyien Chandran
Chris Lixian Tan
Peiling Yang
E Shyong Tai
Kay Wei Ping Ng
Joy Vijayan
Yee Cheun Chan
Li Ling Tan
Martin Beng-Huat Lee
Horng Ruey Chua
Wei Zhen Hong
Eng Soo Yap
Dawn K. Lim
Yew Sen Yuen
Yiong Huak Chan
Folefac Aminkeng
Alvin Seng Cheong Wong
Yiqing Huang
Sen Hee Tay
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
Cancers
neutrophil-to-lymphocyte ratio
immunotherapy
immune-related adverse events
survival
author_facet Pei Yi Lee
Kellynn Qi Xuan Oen
Grace Rui Si Lim
Juanda Leo Hartono
Mark Muthiah
Daniel Q. Huang
Felicia Su Wei Teo
Andrew Yunkai Li
Anselm Mak
Nisha Suyien Chandran
Chris Lixian Tan
Peiling Yang
E Shyong Tai
Kay Wei Ping Ng
Joy Vijayan
Yee Cheun Chan
Li Ling Tan
Martin Beng-Huat Lee
Horng Ruey Chua
Wei Zhen Hong
Eng Soo Yap
Dawn K. Lim
Yew Sen Yuen
Yiong Huak Chan
Folefac Aminkeng
Alvin Seng Cheong Wong
Yiqing Huang
Sen Hee Tay
author_sort Pei Yi Lee
title Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
title_short Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
title_full Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
title_fullStr Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
title_full_unstemmed Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
title_sort neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-03-01
description The utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of cancer patients who received at least one dose of ICI in a tertiary hospital. We examined NLR and PLR in irAE cases and controls. Logistic and Cox regression models were used to identify independent risk factors for irAEs, progression-free survival (PFS), and overall survival (OS). The study included 91 patients with irAEs and 56 controls. Multiple logistic regression showed that NLR < 3 at baseline was associated with higher occurrence of irAEs. Multivariate Cox regression showed that development of irAEs and reduction in NLR from baseline to week 6 were associated with longer PFS. Higher NLR values at baseline and/or week 6 were independently associated with shorter OS. A reduction in NLR from baseline to week 6 was associated with longer OS. In this study of cancer patients treated with ICIs, NLR has a bidirectional relationship with adverse outcomes. Lower NLR was associated with increased occurrence of irAEs while higher NLR values were associated with worse clinical outcomes.
topic neutrophil-to-lymphocyte ratio
immunotherapy
immune-related adverse events
survival
url https://www.mdpi.com/2072-6694/13/6/1308
work_keys_str_mv AT peiyilee neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT kellynnqixuanoen neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT graceruisilim neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT juandaleohartono neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT markmuthiah neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT danielqhuang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT feliciasuweiteo neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT andrewyunkaili neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT anselmmak neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT nishasuyienchandran neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT chrislixiantan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT peilingyang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT eshyongtai neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT kayweipingng neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT joyvijayan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT yeecheunchan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT lilingtan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT martinbenghuatlee neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT horngrueychua neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT weizhenhong neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT engsooyap neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT dawnklim neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT yewsenyuen neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT yionghuakchan neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT folefacaminkeng neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT alvinsengcheongwong neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT yiqinghuang neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
AT senheetay neutrophiltolymphocyteratiopredictsdevelopmentofimmunerelatedadverseeventsandoutcomesfromimmunecheckpointblockadeacasecontrolstudy
_version_ 1724220328906850304
spelling doaj-819b9f81de8649f18c8021bf0cf1e2702021-03-16T00:02:19ZengMDPI AGCancers2072-66942021-03-01131308130810.3390/cancers13061308Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control StudyPei Yi Lee0Kellynn Qi Xuan Oen1Grace Rui Si Lim2Juanda Leo Hartono3Mark Muthiah4Daniel Q. Huang5Felicia Su Wei Teo6Andrew Yunkai Li7Anselm Mak8Nisha Suyien Chandran9Chris Lixian Tan10Peiling Yang11E Shyong Tai12Kay Wei Ping Ng13Joy Vijayan14Yee Cheun Chan15Li Ling Tan16Martin Beng-Huat Lee17Horng Ruey Chua18Wei Zhen Hong19Eng Soo Yap20Dawn K. Lim21Yew Sen Yuen22Yiong Huak Chan23Folefac Aminkeng24Alvin Seng Cheong Wong25Yiqing Huang26Sen Hee Tay27Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeBiostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 119228, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore 119228, SingaporeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, SingaporeThe utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) utility in predicting immune-related adverse events (irAEs) and survival have not been well studied in the context of treatment with immune checkpoint inhibitors (ICIs). We performed a case-control study of cancer patients who received at least one dose of ICI in a tertiary hospital. We examined NLR and PLR in irAE cases and controls. Logistic and Cox regression models were used to identify independent risk factors for irAEs, progression-free survival (PFS), and overall survival (OS). The study included 91 patients with irAEs and 56 controls. Multiple logistic regression showed that NLR < 3 at baseline was associated with higher occurrence of irAEs. Multivariate Cox regression showed that development of irAEs and reduction in NLR from baseline to week 6 were associated with longer PFS. Higher NLR values at baseline and/or week 6 were independently associated with shorter OS. A reduction in NLR from baseline to week 6 was associated with longer OS. In this study of cancer patients treated with ICIs, NLR has a bidirectional relationship with adverse outcomes. Lower NLR was associated with increased occurrence of irAEs while higher NLR values were associated with worse clinical outcomes.https://www.mdpi.com/2072-6694/13/6/1308neutrophil-to-lymphocyte ratioimmunotherapyimmune-related adverse eventssurvival